Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 3/20 | 0.55 |
| ▸ | CHAT | P28329 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anazolene SCHEMBL26460213 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL29387597 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL1476742 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL11148088 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL23595 | 0.99 | MEN1 (0.98) | MEN1THRBKMT2ASNCACHAT | |
| SCHEMBL26459262 | 0.95 | MEN1 (0.91) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL1649427 | 0.87 | KMT2A (0.76) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL29374551 | 0.87 | KMT2A (0.76) | MEN1THRBKMT2ASNCACHAT | |
| Anazolene SCHEMBL23594 | 0.87 | KMT2A (0.76) | MEN1THRBKMT2ASNCACHAT | |
| SCHEMBL12177943 | 0.83 | MEN1 (0.71) | MEN1THRBKMT2ASNCACHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080209-A | Anti-CTLA-4 binding proteins and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12622969-B2 | Methods for treatment using anti-α4β7 antibody | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| US-12606836-B2 | Process for extracellular secretion of Brazzein | MAGELLAN LIFE SCIENCES LTD. (GB) | 2026-04-21 | — | — | US | disclosed |
| US-12606596-B2 | Self-assembling insect ferritin nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-04-21 | — | — | US | disclosed |
| US-12582702-B2 | Methods for improving leptin sensitivity for the treatment of obesity and diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-24 | — | — | US | disclosed |
| US-12544445-B2 | Methods for treatment using anti-α4β7 antibody | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12540198-B2 | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof | ZYMEWORKS BC INC. (CA) | 2026-02-03 | — | — | US | disclosed |
| US-12516371-B2 | Msp nanopores and related methods | UNIVERSITY OF WASHINGTON (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250387464-A1 | RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2025-12-25 | — | — | US | disclosed |
| CN-107849126-B | Heavy chain-only anti-ANG-2 antibodies | 阿勒根公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220098286-A1 | NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2022-03-31 | — | — | US | disclosed |
| US-11286293-B2 | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof | ZYMEWORKS, INC. (CA) | 2022-03-29 | — | — | US | disclosed |
| WO-2022058764-A1 | SKIN PATCH TEST FOR THE DIAGNOSIS OF IMMUNOLOGICAL PROTECTION AGAINST SARS-COV-2 VIRUS INFECTION | SEMMELWEIS EGYETEM (HU) | 2022-03-24 | — | — | WO | disclosed |
| US-20220073963-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING TYPE 1 DIABETES AND OTHER AUTOIMMUNE DISEASES | UNIV JOHNS HOPKINS (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220064298-A1 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4 | MOMENTA PHARMACEUTICALS, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220064323-A1 | Therapeutic Anti-CD9 Antibody | KLING BIOTHERAPEUTICS B.V. (NL) | 2022-03-03 | — | — | US | disclosed |
| US-20220049019-A1 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | MOMENTA PHARMACEUTICALS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220043001-A1 | METHODS AND COMPOSITIONS FOR DETECTING MISFOLDED PROTEINS | YALE UNIVERSITY (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3950852-A1 | AQUEOUS INK COMPOSITION FOR WRITING INSTRUMENTS | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540198-B2 | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof | CLTB, CLTC, CLTA | MEN1 3118/4885THRB 169/4885KMT2A 282/4885 |
| US-20250387464-A1 | RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE | METTL16, UPF1, SET | MEN1 475/4885THRB 1977/4885KMT2A 2591/4885 |
| US-12582702-B2 | Methods for improving leptin sensitivity for the treatment of obesity and diabetes | ADIPOR1, ADIPOR2, GLP1R | MEN1 2384/4885THRB 19/4885KMT2A 969/4885 |
| US-12606596-B2 | Self-assembling insect ferritin nanoparticles | FTH1, TFRC, FEM1B | MEN1 2086/4885THRB 483/4885KMT2A 1592/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | MEN1 3545/4885THRB 774/4885KMT2A 2734/4885 |
| US-12544445-B2 | Methods for treatment using anti-α4β7 antibody | ITGA4, ITGB7, VSIG8 | MEN1 4740/4885THRB 481/4885KMT2A 1672/4885 |
| US-12606836-B2 | Process for extracellular secretion of Brazzein | HM13, SPPL2A, SPPL2B | MEN1 2603/4885THRB 880/4885KMT2A 4492/4885 |
| US-12622969-B2 | Methods for treatment using anti-α4β7 antibody | ITGA4, ITGB7, ITGAV | MEN1 4819/4885THRB 446/4885KMT2A 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.